Company Profile

Washburn Therapeutics Inc
Profile last edited on: 7/17/14      CAGE: 4TSV1      UEI:

Business Identifier: Development of biologically active gels controlling inflammation by selectively neutralizing pro-inflammatory cytokines based on a technology being licensed exclusively by the company. Preliminary results of these gels have demonstrated that conjugates of antibodies against tumor necrosis factor-alpha and hyaluronic acid were able to reduce secondary necrosis in a partial-thickness rat burn model by 70% This technology could mean the possible prevention of burn progression through local control of inflammatory responses and overall improvement of healing outcomes.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6743 Wilkins Avenue
Pittsburgh, PA 15217
Location: Single
Congr. District: 18
County: Allegheny

Public Profile

Washburn Therapeutics, Inc. is developing a new class of polymer therapeutics to treat a broad range of inflammatory conditions. Polymer therapeutics is an emerging class of drug that conjugates a known therapeutic agent to a polymer in order to provide targeted delivery. The technology was developed from Carnegie Mellon University and has been licensed exclusively by the firm. Polymer therapeutics work by using a polymer conjugation in order to localize the effects of antibody inhibitors of tumor necrosis factor- a protein known as the central mediator of inflammation. These antibodies form the basis for a $13 Billion Dollar sector of the biotechnology industry and significant safety concerns have been raised because of their powerful immunosuppressive effects. By localizing the delivery of TNF-ainhibitors, it may be possible to treat psoriasis, burns, chronic wounds, and other conditions characterized by intense, local inflammation without many of the side-effects observed through standard administering of the unconjugated drug.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 1 DHA $150,000
Project Title: Reduction of Burn Progression and Scar Contracture with Cytokine-Neutralizing Gels
2010 1 NIH $185,770
Project Title: Development Of Cytokine-Inhibiting Gels For Treating Chronic Wounds

Key People / Management

  Newell R Washburn -- President

Company News

There are no news available.